The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).

Cancer Chemother Pharmacol · 2012 · PMC3456942 · PMID 22886005

Europe PMC DOI

hedged sentence

0.0023

closest p · 0.0× alpha

0.0023

boldest claim

The sentences

did not reach statistical significanceP = 0.0023actually significant

reported that addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS, although OS did not reach statistical significance, and the RR was not improved (PFS: 9.4 vs. 8.0 months [HR: 0.83; P = 0.0023], OS: 21.3 vs. 19.9 months [HR: 0.89; P = 0.077]) [ 7 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.